From: HPV catch-up vaccination of young women: a systematic review and meta-analysis
Outcomes | Illustrative comparative risks* (95% CI) | Relative effect (95% CI) | No of Participants (studies) | Quality of the evidence (GRADE) | |
---|---|---|---|---|---|
Assumed risk | Corresponding risk | ||||
Placebo, no vaccine or other vaccines | HPV vaccines | ||||
Cancer mortality & | |||||
Cervical cancer & | |||||
CIN 2+ ITT (any HPV type) (4-year follow-up) | 51 per 1000 | 41 per 1000 (32 to 52) | RR 0.8 (0.62 to 1.02) | 39381 (5 studies) | ⊕⊕⊕⊝ moderate1,2 |
CIN2+ PPP (any HPV type) (4-year follow-up) | 29 per 1000 | 14 per 1000 (6 to 34) | RR 0.49 (0.21 to 1.14) | 1096 (1 study) | ⊕⊕⊝⊝ low2,3 |
CIN2+ ITT (any HPV type) (6-year follow-up) | 34 per 1000 | 10 per 1000 (4 to 27) | RR 0.29 (0.11 to 0.78) | 1002 (1 study) | ⊕⊕⊕⊝ moderate2,4 |
CIN2+ ITT (any HPV type) (8-year follow-up) | 85 per 1000 | 54 per 1000 (23 to 128) | RR 0.64 (0.27 to 1.52) | 290 (1 study) | ⊕⊕⊝⊝ low2,5,6 |
CIN2+ lesions ITT (HPV 16 and/or 18 related) (4- year follow up) | 22 per 1000 | 12 per 1000 (10 to 14) | RR 0.54 (0.44 to 0.67) | 42652 (7 studies) | ⊕⊕⊕⊕ high2 |
CIN2+ ITT (HPV 16 and/or 18 related) (8-year follow-up) | 31 per 1000 | 9 per 1000 (3 to 30) | RR 0.29 (0.09 to 0.96) | 721 (2 studies) | ⊕⊕⊕⊝ moderate4,7 |
CIN2+ PPP (HPV (16 and/or 18 related) (4- year follow up) | 11 per 1000 | 1 per 1000 (0 to 2) | RR 0.05 (0.01 to 0.16) | 35023 (6 studies) | ⊕⊕⊕⊕ high2 |
Genital warts ITT (any HPV type) (4-year follow-up) | 40 per 1000 | 15 per 1000 (13 to 19) | RR 0.38 (0.31 to 0.47) | 17391 (2 studies) | ⊕⊕⊕⊕ high2 |
Genital warts ITT (HPV 6 and/or 11 related) (4-5 year follow up) | 30 per 1000 | 8 per 1000 (4 to 19) | RR 0.28 (0.12 to 0.65) | 21686 (4 studies) | ⊕⊕⊕⊕ high2 |
VIN2+ and VaIN2+ ITT (any HPV type) (4-year follow-up) | 7 per 1000 | 3 per 1000 (2 to 5) | RR 0.49 (0.32 to 0.76) | 17391 (2 studies) | ⊕⊕⊕⊝ moderate2,4 |
VIN2+ and VaIN 2+ ITT (HPV related) (4-5-year follow-up) | 4 per 1000 | 3 per 1000 (0 to 60) | RR 0.72 (0.03 to 15.02) | 21694 (4 studies) | ⊕⊕⊝⊝ low1,6 |
Serious Adverse Events (Follow-up: >7 months8, longest reported follow up) | 44 per 1000 | 44 per 1000 (40 to 48) | RR 0.99 (0.91 to 1.08) | 43342 (14 studies) | ⊕⊕⊕⊝ moderate2,9 |